These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 1648791)

  • 41. Advantages of low molecular weight heparin over standard heparin: facts and fiction.
    Vinazzer H
    Semin Thromb Hemost; 1991 Oct; 17(4):385-8. PubMed ID: 1666459
    [No Abstract]   [Full Text] [Related]  

  • 42. Engineered thrombin aims to take on heparin.
    Erdmann J
    Chem Biol; 2010 Dec; 17(12):1267-8. PubMed ID: 21168759
    [No Abstract]   [Full Text] [Related]  

  • 43. Facts and artefacts of coagulation assays for factor Xa inhibitors.
    Haas S
    Thromb Haemost; 2010 Apr; 103(4):686-8. PubMed ID: 20174751
    [No Abstract]   [Full Text] [Related]  

  • 44. [Current pharmacological aspects of antithrombotic drugs].
    Stroescu V
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1976; 28(5):325-7. PubMed ID: 14367
    [No Abstract]   [Full Text] [Related]  

  • 45. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.
    Cella G; Girolami A; Sasahara AA
    Circulation; 1999 Jun; 99(25):3323. PubMed ID: 10385510
    [No Abstract]   [Full Text] [Related]  

  • 46. Interindividual variability of in vitro response to anticoagulants.
    Samama MM
    Thromb Res; 2011 Jan; 127(1):1. PubMed ID: 21075429
    [No Abstract]   [Full Text] [Related]  

  • 47. Pharmacokinetics of Clivarin a new low molecular weight heparin in healthy volunteers.
    Andrassy K; Eschenfelder V; Koderisch J; Weber E
    Thromb Res; 1994 Jan; 73(2):95-108. PubMed ID: 7802862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of coagulation and platelet adhesion to extracellular matrix by unfractionated heparin and a low molecular weight heparin.
    Krupinski K; Basic-Micic M; Lindhoff E; Breddin HK
    Blut; 1990 Nov; 61(5):289-94. PubMed ID: 2176900
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Fibrinolytic and anticoagulant complexes of low-molecular heparin with tuftsin].
    Kudriashov BA; Ashmarin IP; Liapina LA; Pastorova VE
    Biull Eksp Biol Med; 1992 Dec; 114(12):609-11. PubMed ID: 1337992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The in vitro response to low-molecular-weight heparin is not age-dependent in children.
    Ignjatovic V; Summerhayes R; Newall F; Monagle P
    Thromb Haemost; 2010 Apr; 103(4):855-6. PubMed ID: 20174765
    [No Abstract]   [Full Text] [Related]  

  • 51. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Changes in coagulation, fibrinolysis and platelet functions during extracorporeal circulation].
    Kaizu K; Uriu K; Ikeda M
    Nihon Rinsho; 2004 May; 62 Suppl 5():46-9. PubMed ID: 15197886
    [No Abstract]   [Full Text] [Related]  

  • 53. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies.
    Vinazzer H; Woler M
    Thromb Res; 1985 Oct; 40(2):135-46. PubMed ID: 3878009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of thrombin-receptors of thrombocytes for the interaction of heparins and low-molecular-weight heparin in human whole blood clotting.
    Harenberg J; Schuler M; Zimmermann R; Heptner W
    Haemostasis; 1988; 18 Suppl 3():20-2. PubMed ID: 2840370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abnormal coagulation in the postoperative period contributing to excessive bleeding.
    McKenna R
    Med Clin North Am; 2001 Sep; 85(5):1277-310, viii. PubMed ID: 11565500
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin.
    Hansen JB; Naalsund T; Sandset PM; Svensson B
    Thromb Res; 2000 Dec; 100(5):413-7. PubMed ID: 11150584
    [No Abstract]   [Full Text] [Related]  

  • 57. Heparin and low molecular weight heparin: background and pharmacology.
    Morris TA
    Clin Chest Med; 2003 Mar; 24(1):39-47. PubMed ID: 12685055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fondaparinux sodium: a selective inhibitor of factor Xa.
    Bauer KA
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S14-7. PubMed ID: 11715834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Update on pharmacology of antiplatelets, anticoagulants, and thrombolytics.
    Cheng-Ching E; Samaniego EA; Naravetla BR; Zaidat OO; Hussain MS
    Neurology; 2012 Sep; 79(13 Suppl 1):S68-76. PubMed ID: 23008416
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors.
    Kokolis S; Cavusoglu E; Clark LT; Marmur JD
    Prog Cardiovasc Dis; 2004; 46(6):506-23. PubMed ID: 15224257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.